Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.

被引：0
|
作者：
Li, Jian
Xu, Ye
Zang, Aimin
Gao, Yunong
Gao, Quanli
Zhang, Yanqiao
Wang, Dong
Xu, Jianming
Yuan, Ying
Jiang, Haiping
Ying, Jieer
Shi, Chunmei
Deng, Yanhong
Wang, Jing
Liu, Tianshu
Huang, Yi
Xu, Yaling
Wang, Yidi
Fei, Cong
Shen, Lin
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Fudan Univ Shanghai, Canc Ctr, Shanghai, Peoples R China
[3] Hebei Univ, Affiliated Hosp, Hebei, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[5] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[6] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[8] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Zhejiang, Peoples R China
[9] Med Sch Zhejiang Univ, Affiliated Hosp 1, Zhejiang, Peoples R China
[10] Zhejiang Canc Hosp, Beijing, Peoples R China
[11] Fujian Med Univ, Union Hop, Fujian, Peoples R China
[12] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
[13] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[14] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[15] Hubei Canc Hosp, Wuhan, Hubei, Peoples R China
[16] BeiGene Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14556
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Primary analysis of GEICO 120/DORA, a real-world multicentre study of dostarlimab in patients with recurrent or advanced DNA mismatch repair deficient/microsatellite instability-high (DMMR/MSI-H) endometrial cancer
    Gallego, Alejandro
    Madariaga, Ainhoa
    Estevez-Garcia, Purificacion
    Alberti, Facundo
    Carbo, Anna
    Palacio, Isabel
    Churruca, Cristina
    Galvez, Fernando
    Ortega, M. Eugenia
    Murata, Paola
    Manzano, Aranzazu
    Masvidal, Maria
    Martin-Lorente, Cristina
    Hernando, Blanca
    Lozano, Inmaculada
    Cueva, Juan F.
    Garcia-Illescas, David
    Falco, Esther
    Mendiola, Marta
    Redondo, Andres
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A182 - A182
  • [43] Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad A.
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana N.
    Miller, Rowan
    Pikiel, Joanna
    Mirza, Mansoor Raza
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer Taylor
    Tinker, Anna
    Powell, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study
    Cohen, Romain
    Bennouna, Jaafar
    Henriques, Julie
    Tournigand, Christophe
    De La Fouchardiere, Christelle
    Tougeron, David
    Borg, Christophe
    Mazard, Thibault
    Chibaudel, Benoist
    Garcia-Larnicol, Marie-Line
    Svrcek, Magali
    Vernerey, Dewi
    Menu, Yves
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [45] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
    Shiu, K. K.
    Andre, T.
    Kim, T. W.
    Jensen, B. Vittrup
    Jensen, L. H.
    Punt, C. J. A.
    Smith, D.
    Garcia-Carbonero, R.
    Alcaide-Garcia, J.
    Gibbs, P.
    De la Fouchardiere, C.
    Rivera, F.
    Fernandez, M. E. Elez
    Le, D. T.
    Yoshino, T.
    Zuo, Y.
    Fogelman, D.
    Adelberg, D. E.
    Diaz, L. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1271 - S1272
  • [46] Camrelizumab in advanced or metastatic solid tumor patients with microsatellite instability-high/mismatch repair-deficient: Results from an open-label exploratory study.
    Chen, Jingde
    Quan, Ming
    Chen, Zhiqin
    Zeng, Tianmei
    Li, Yandong
    Zhou, Ying
    Hai, Yanan
    Gao, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
    Berton-Rigaud, D.
    Pautier, P.
    Lorusso, D.
    Gennigens, C.
    Gladieff, L.
    Kryzhanivska, A.
    Bowman, J.
    Tian, C.
    Cornfeld, M.
    Van Gorp, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S517 - S517
  • [48] Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.
    Qin, Shukui
    Li, Jin
    Zhong, Haijun
    Jin, Chuan
    Chen, Lili
    Yuan, Xianglin
    Fan, Qingxia
    Chen, Kehe
    Cao, Peiguo
    Xiao, Jianjun
    Jiang, Da
    Zhang, Tao
    Zhang, Hongyu
    Wang, Xicheng
    Wang, Wei
    Wang, Qingyu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
    Yoshino, T.
    Andre, T.
    Kim, T. W.
    Yong, W. P.
    Shiu, K-K.
    Jensen, B. Vittrup
    Jensen, L. H.
    Punt, C. J. A.
    Smith, D.
    Garcia-Carbonero, R.
    Alcaide-Garcia, J.
    Gibbs, P.
    de la Fouchardiere, C.
    Rivera, F.
    Elez Fernandez, M. E.
    Le, D. T.
    Zuo, Y.
    Fogelman, D.
    Adelberg, D. E.
    Diaz, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1502 - S1503
  • [50] Evaluating the patient-level association between progression-free survival and overall survival in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (MSI-H/dMMR mCRC) treated with immune checkpoint inhibitors
    Roodhart, J. M. L.
    Sharpe, D. J.
    Tate, A. E.
    Bertwistle, D.
    Dixon, M.
    Chen, H-H.
    Kurt, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S27 - S27
12345